# An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

> **NCT05594992** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **JCR Pharmaceuticals Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **DRUG:** JR-141

## Key facts

- **NCT ID:** NCT05594992
- **Lead sponsor:** JCR Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-02-22
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594992, "An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05594992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*